Keara Redmond
Overview
Explore the profile of Keara Redmond including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
85
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schoenpflug L, Chatzipli A, Sirinukunwattana K, Richman S, Blake A, Robineau J, et al.
J Pathol
. 2024 Dec;
265(2):184-197.
PMID: 39710952
Tumour content plays a pivotal role in directing the bioinformatic analysis of molecular profiles such as copy number variation (CNV). In clinical application, tumour purity estimation (TPE) is achieved either...
2.
Leonard N, Corry S, Reidy E, Egan H, OMalley G, Thompson K, et al.
iScience
. 2024 Sep;
27(9):110701.
PMID: 39310770
CMS4 colorectal cancer (CRC), based on the consensus molecular subtype (CMS), stratifies patients with the poorest disease-free survival rates. It is characterized by a strong mesenchymal stromal cell (MSC) signature,...
3.
Domingo E, Rathee S, Blake A, Samuel L, Murray G, Sebag-Montefiore D, et al.
EBioMedicine
. 2024 Jul;
106:105228.
PMID: 39013324
Background: It is uncertain which biological features underpin the response of rectal cancer (RC) to radiotherapy. No biomarker is currently in clinical use to select patients for treatment modifications. Methods:...
4.
Egan H, Treacy O, Lynch K, Leonard N, OMalley G, Reidy E, et al.
Cell Rep
. 2023 May;
42(5):112475.
PMID: 37167967
Immunosuppressive tumor microenvironments (TMEs) reduce the effectiveness of immune responses in cancer. Mesenchymal stromal cells (MSCs), precursors to cancer-associated fibroblasts (CAFs), promote tumor progression by enhancing immune cell suppression in...
5.
Dunne P, McArt D, Blayney J, Kalimutho M, Greer S, Wang T, et al.
Clin Cancer Res
. 2013 Oct;
20(1):164-75.
PMID: 24170546
Purpose: Despite the use of 5-fluorouracil (5-FU)-based adjuvant treatments, a large proportion of patients with high-risk stage II/III colorectal cancer will relapse. Thus, novel therapeutic strategies are needed for early-stage...